Primary central nervous system lymphoma

Current Opinion in Neurology

Volumn 22, Issue 6, 2009, Pages 675-680

  Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Molecular genetic characteristics; Primary central nervous system lymphoma; Treatment

Indexed keywords

CYTARABINE; GADOLINIUM; IBRITUMOMAB TIUXETAN; METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN;

BRAIN RADIATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR GENETICS; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER; REVIEW;

CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 74049139859     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328332533b     Document Type: Review

References (56)

1. Gerstner E, Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther 2007; 7:689-700.
2. Bessell EM, Hoang-Xuan K, Ferreri AJ, Reni M. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer 2007; 43:1141-1152. (Pubitemid 46590731)
3. CBTRUS. Statistical report: primary brain tumors in the United States, 2000-2004. Published by the Central Brain Tumor Registry of the United States 2008.
4. Abrey LE, Batchelor TT, Ferreri AJ, et al., International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23:5034-5043.
5. Di Noto R, Scalia G, Abate G, et al. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leuk Res 2008; 32:1196-1199.
6. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496-502.
7. Fischer L, Martus P, Weller M, et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 2008; 71:1102-1108.
8. Kraan J, Gratama JW, Haioun C, et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom 2008; chapter 6:unit 6.25.
9. Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008; 10:223-228.
10. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24:5711-5715.
11. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21:266-272.
12. Reiche W, Hagen T, Schuchardt V, Billmann P. Diffusion-weighted MR imaging improves diagnosis of CNS lymphomas. A report of four cases with common and uncommon imaging features. Clin Neurol Neurosurg 2007; 109:92-101.
13. Kosaka N,TsuchidaT, Uematsu H, et al. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol 2008; 190:W365-W369.
14. Karantanis D, O'Neill BP, Subramaniam RM, et al. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 2007; 28:834-841.
15. Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006; 33:164-168.
16. MasadaT, Matsumoto Y, Kawai N, et al. Usefulness of FDG-PET in monitoring effects of the modality therapy for central nervous system malignant lymphoma: report of three cases. No Shinkei Geka 2004; 32:859-864.
17. ShenkierTN, Blay JY, O'Neill BP, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005; 23:2233-2239.
18. Jahnke K, Korfel A, O'Neill BP, et al. International study on low-grade primary central nervous system lymphoma. Ann Neurol 2006; 59:755-762. (Pubitemid 43673153)
19. Gerstner ER, Abrey LE, Schiff D, et al. CNS Hodgkin lymphoma. Blood 2008; 112:1658-1661.
20. Cady FM, O'Neill BP, Law ME, etal. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 2008; 26:4814-4819.
21. Matsumoto T, Kumagai J, Hasegawa M, et al. Significant increase in the expression of matrix metalloproteinase 7 in primary CNS lymphoma. Neuro pathology 2008; 28:277-285.
22. Kinoshita M, Izumoto S, Hashimoto N, etal. Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lym phomas: a study comparing primary CNS malignant and CNS intravascular lymphomas. Brain Tumor Pathol 2008; 25:73-78.
23. Chu LC, Eberhart CG, Grossman SA, Herman JG. Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 2006; 119:2487-2491.
24. Rubenstein JL, Fridlyand J,Shen A, etal. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006; 107:3716-3723.
25. Courts C, Montesinos-Rongen M, Brunn A, etal. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. Neuropathol Exp Neurol 2008; 67:720-727.
26. Booman M, Szuhai K, Rosenwald A, Hartmann E, etal. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216:209-217.
27. Angelov L, Doolittle ND, Kraemer DF, etal. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multiinstitutional experience. J Clin Oncol 2009; 27:3503-3509.
28. Ferreri AJM, Reni M, Foppoli M, et al. Randomized phase II trial on primary chemotherapy with high-dose methotrexate alone or associated with high-dose cytarabine for patients with primary CNS lymphoma (IELSG #20 Trial): tolerability, activity and event-free survival analysis [ASH Annual Meeting abstract]. Blood 2008; 112:3062.
29. Shah GD, Yahalom J, Correa DD, etal. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lym phoma. J Clin Oncol 2007; 25:4730-4735.
30. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood 2009; 113:3896-3902.
31. Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38:417-420.
32. Ilerhaus G, Marks R, Ihorst G, etal. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24:3865-3870.
33. Panageas KS, Elkin EB, Ben-Porat L, et al. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007; 110:1338-1344.
34. Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11:211-215.
35. Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007; 85:207-211.
36. Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004; 62:548-555.
37. Neuwelt EA, Goldman DL, Dahlborg SA, etal. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 999:1580-1590.
38. Fliessbach K, Helmstaedter C, Urbach H, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005; 64:1184-1188.
39. Correa DD, Maron L, Harder H, etal. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18:1145-1151.
40. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoen-cephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004; 62:451-456.
41. Linnebank M, Moskau S, Jurgens A, et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol 2009; 11:2-8.
42. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 2005; 26:258-265.
43. Nussenblatt RB, Chan CC, Wilson WH, et al., CNS and Ocular Lymphoma Workshop Group. International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future. Ocul Immunol Inflamm 2006; 14:139-144.
44. Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008; 71:1355-1360.
45. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007; 18:1851-1855.
46. Kreisl TN, Panageas KS, Elkin EB, et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma 2008; 49:1710-1716.
47. Corcoran C, Rebe K, van der Plas H, et al. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 2008; 42:433-436.
48. Gasser O, Bihl FK, Wolbers M, et al., Swiss HIV Cohort Study. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007; 4:e96.
49. Soussain C, Hoang-Xuan K, Taillandier L, et al., Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26:2512-2518.
50. Iwamoto FM, Schwartz J, Pandit-Taskar N, etal. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 2007; 110:2528-2534.
51. Voloschin AD, Betensky R, Wen PY, et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86:211-215.
52. Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17:1141-1145.
53. Reni M, Mason W, Zaja F, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004; 40:1682-1688.
54. Santisteban M, Nieto Y, De la Cruz S, et al. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clin Transl Oncol 2007; 9:465-467.
55. Akyuz C, Aydin GB, Cila A, et al. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child. Leuk Lymphoma 2007; 48:1253-1255.
56. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25:1350-1356.